Use

NTx (collagen cross‑linked N‑telopeptide) in 24‑hour urine is useful in assessing bone resorption in patients with metabolic bone disease and in monitoring therapy aimed at slowing or halting osteoporotic bone loss. A decline of approximately 30% or more in NTx over a six‑month period is indicative of effective therapy. Reference ranges vary by age and sex, typically expressed as nM bone collagen equivalents per mM creatinine. These results are used primarily for monitoring treatment response in osteoporosis or similar metabolic bone disorders. ([jdos.nicholsinstitute.com](https://jdos.nicholsinstitute.com/dos/prismahealth/test/909418?utm_source=openai))